<div id="readability-page-1">02:39 PM EDT, 05/14/2026 (MT Newswires) -- (Updates with latest stock price movement in the headline and first paragraph, Q1 earnings in the second through sixth paragraphs.)Regenxbio's ( RGNX ) shares were down about 36% in Thursday afternoon trading after its Q1 swung to a loss and revenue declined.The company reported a Q1 net loss Thursday of $1.72 per diluted share, swinging from earnings of $0.12 a year earlier.Analysts polled by FactSet expected a loss of $1.34.Revenue for the quarter ended March 31 fell to $6.4 million from $89.0 million a year earlier.Analysts surveyed by FactSet expected $25.8 million.The company expects its cash, cash equivalents and marketable securities of $150.5 million as of March 31 to fund its operations into early 2027.Separately, the company said Thursday its investigational gene therapy RGX-202 met the primary endpoint in the pivotal phase III portion of the Affinity Duchenne trial for Duchenne Muscular Dystrophy.The company said 93% of patients achieved over 10% microdystrophin expression at week 12.Regenxbio ( RGNX ) said it is preparing to pursue accelerated approval based on the data and is targeting a potential commercial launch in 2027.Price: 6.47, Change: -3.57, Percent Change: -35.56 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

RGNX

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

IBBQ

标普生物技术 ETF - SPDR

Regenxbio 的股价在报告第一季度每股摊薄净亏损 1.72 美元后下跌了 36%，而去年同期的收益为每股 0.12 美元。收入从 8900 万美元降至 640 万美元，未能达到分析师的预期。该公司拥有 1.505 亿美元的现金，可以支持其运营到 2027 年初。然而，其基因疗法 RGX-202 在第三阶段试验中达到了主要终点，计划申请加速批准，并有望在 2027 年进行商业发布

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

fidelity

Regenxbio

Invesco Nasdaq Biotechnology ETF

辉盛研究系统

更新：Regenxbio 股价在第一季度由盈转亏后下跌，收入减少；RGX-202 的第三阶段研究达到了主要终点